Research Analysts’ Recent Ratings Changes for Tempus AI (TEM)

Tempus AI (NASDAQ: TEM) has recently received a number of price target changes and ratings updates:

• 2/19/2026 – Tempus AI is now covered by analysts at Mizuho. They set an “outperform” rating and a $100.00 price target on the stock.
• 2/19/2026 – Tempus AI is now covered by analysts at Mizuho. They set an “outperform” rating and a $100.00 price target on the stock.
• 2/17/2026 – Tempus AI is now covered by analysts at Robert W. Baird. They set an “outperform” rating and a $59.00 price target on the stock.
• 2/17/2026 – Tempus AI is now covered by analysts at Robert W. Baird. They set an “outperform” rating and a $59.00 price target on the stock.
• 1/22/2026 – Tempus AI had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Tempus AI had its price target lowered by analysts at Canaccord Genuity Group Inc. from $95.00 to $80.00. They now have a “buy” rating on the stock.

Insider Buying and Selling

In other news, EVP Erik Phelps sold 1,302 shares of the stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $67.42, for a total transaction of $87,780.84. Following the completion of the transaction, the executive vice president directly owned 89,280 shares in the company, valued at approximately $6,019,257.60. This represents a 1.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Andrew Polovin sold 12,874 shares of Tempus AI stock in a transaction on Monday, November 24th. The stock was sold at an average price of $75.00, for a total transaction of $965,550.00. Following the completion of the sale, the executive vice president owned 107,590 shares of the company’s stock, valued at approximately $8,069,250. This trade represents a 10.69% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 544,188 shares of company stock worth $37,163,496 over the last 90 days. 26.27% of the stock is currently owned by corporate insiders.

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.